🇺🇸 FDA
Patent

US 11739086

Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same

granted A61KA61K31/437A61K31/4545

Quick answer

US patent 11739086 (Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same) held by Aclaris Therapeutics, Inc. expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Aclaris Therapeutics, Inc.
Grant date
Tue Aug 29 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K31/437, A61K31/4545, A61K45/06, A61P